CY1117854T1 - Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση - Google Patents
Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρησηInfo
- Publication number
- CY1117854T1 CY1117854T1 CY20161100721T CY161100721T CY1117854T1 CY 1117854 T1 CY1117854 T1 CY 1117854T1 CY 20161100721 T CY20161100721 T CY 20161100721T CY 161100721 T CY161100721 T CY 161100721T CY 1117854 T1 CY1117854 T1 CY 1117854T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical form
- ophthalmic use
- peptide pharmaceutical
- local ophthalmic
- local
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Φαρμακοτεχνική μορφή με πεπτίδια για τοπική οφθαλμική χρήση και η χρησιμοποίηση τους στη θεραπεία και/ή στην τοπική πρόληψη οφθαλμικών νόσων και κατά προτίμηση νόσων του οπισθίου τμήματος του οφθαλμού.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931242A ES2362604B1 (es) | 2009-12-22 | 2009-12-22 | Formulación tópica oftálmica de péptidos. |
PCT/EP2010/007737 WO2011076368A2 (en) | 2009-12-22 | 2010-12-17 | Topical ophthalmic peptide formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117854T1 true CY1117854T1 (el) | 2017-05-17 |
Family
ID=43928893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100721T CY1117854T1 (el) | 2009-12-22 | 2016-07-22 | Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση |
Country Status (34)
Country | Link |
---|---|
US (1) | US9216208B2 (el) |
EP (1) | EP2515870B1 (el) |
JP (1) | JP5920928B2 (el) |
KR (1) | KR101657737B1 (el) |
CN (1) | CN102753153B (el) |
AR (1) | AR079683A1 (el) |
AU (1) | AU2010335595B2 (el) |
BR (1) | BR112012015386B8 (el) |
CA (1) | CA2785104C (el) |
CL (1) | CL2012001737A1 (el) |
CO (1) | CO6592047A2 (el) |
CY (1) | CY1117854T1 (el) |
DK (1) | DK2515870T3 (el) |
ES (2) | ES2362604B1 (el) |
HK (1) | HK1178049A1 (el) |
HR (1) | HRP20160954T1 (el) |
HU (1) | HUE028193T2 (el) |
IL (1) | IL220584A (el) |
LT (1) | LT2515870T (el) |
MX (1) | MX338323B (el) |
MY (1) | MY178169A (el) |
NZ (1) | NZ600627A (el) |
PL (1) | PL2515870T3 (el) |
PT (1) | PT2515870T (el) |
RS (1) | RS54953B1 (el) |
RU (1) | RU2561585C2 (el) |
SG (1) | SG181727A1 (el) |
SI (1) | SI2515870T1 (el) |
SM (1) | SMT201600277B (el) |
TW (1) | TWI548416B (el) |
UA (1) | UA108484C2 (el) |
UY (1) | UY33153A (el) |
WO (1) | WO2011076368A2 (el) |
ZA (1) | ZA201204522B (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6368722B2 (ja) | 2013-03-01 | 2018-08-01 | フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ | 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド |
GB201516066D0 (en) | 2015-09-10 | 2015-10-28 | Young & Co Llp D | Treatment of retinitis pigmentosa |
CN106822182A (zh) * | 2016-12-27 | 2017-06-13 | 广州姿生生物科技有限公司 | 一种细胞提取物及其用途 |
KR102679493B1 (ko) | 2017-01-31 | 2024-07-01 | 킴벌리-클라크 월드와이드, 인크. | 벤조산 에스테르를 포함하는 항균 조성물 및 이를 이용한 세균 생장 억제 방법 |
US20180325993A1 (en) | 2017-05-15 | 2018-11-15 | Sun Pharmaceutical Industries Limited | Octreotide injection |
TW202133845A (zh) * | 2019-11-21 | 2021-09-16 | 韓商三進製藥股份有限公司 | 用於預防或治療眼部疾病之眼用組合物 |
KR20230133595A (ko) * | 2022-03-11 | 2023-09-19 | 한국한의약진흥원 | 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182258A (en) | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
EP0966271A1 (en) * | 1997-11-06 | 1999-12-29 | Orbon Corporation | Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same |
CA2263042A1 (en) * | 1999-02-25 | 2000-08-25 | Robert W.A. Kuijpers | Treatment of edema |
EP1040837A3 (en) | 1999-02-26 | 2002-01-02 | Erasmus Universiteit Rotterdam | Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder |
WO2002009739A1 (en) * | 2000-07-27 | 2002-02-07 | Novartis Ag | Treatment of ocular disorders with somatostatin analogues |
TWI260228B (en) * | 2002-12-31 | 2006-08-21 | Ind Tech Res Inst | Delivery carrier of presenting cell of somatostatin receptor |
US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
WO2005009356A2 (en) | 2003-07-15 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
US20070082841A1 (en) * | 2005-09-27 | 2007-04-12 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
RU2010114034A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Терапевтическое применение нейропептида ei и acth 7-38 и их комбинаций |
EP2052716B1 (en) | 2007-10-24 | 2014-12-31 | Camurus AB | Controlled release formulations |
-
2009
- 2009-12-22 ES ES200931242A patent/ES2362604B1/es not_active Expired - Fee Related
-
2010
- 2010-12-17 US US13/518,617 patent/US9216208B2/en active Active
- 2010-12-17 EP EP10810911.7A patent/EP2515870B1/en active Active
- 2010-12-17 CN CN201080063430.8A patent/CN102753153B/zh active Active
- 2010-12-17 LT LTEP10810911.7T patent/LT2515870T/lt unknown
- 2010-12-17 JP JP2012545144A patent/JP5920928B2/ja active Active
- 2010-12-17 SG SG2012044178A patent/SG181727A1/en unknown
- 2010-12-17 SI SI201031249A patent/SI2515870T1/sl unknown
- 2010-12-17 UA UAA201207318A patent/UA108484C2/ru unknown
- 2010-12-17 DK DK10810911.7T patent/DK2515870T3/en active
- 2010-12-17 RU RU2012126028/15A patent/RU2561585C2/ru active
- 2010-12-17 PT PT108109117T patent/PT2515870T/pt unknown
- 2010-12-17 CA CA2785104A patent/CA2785104C/en active Active
- 2010-12-17 BR BR112012015386A patent/BR112012015386B8/pt active IP Right Grant
- 2010-12-17 MY MYPI2012002758A patent/MY178169A/en unknown
- 2010-12-17 ES ES10810911.7T patent/ES2587828T3/es active Active
- 2010-12-17 WO PCT/EP2010/007737 patent/WO2011076368A2/en active Application Filing
- 2010-12-17 RS RS20160598A patent/RS54953B1/sr unknown
- 2010-12-17 PL PL10810911.7T patent/PL2515870T3/pl unknown
- 2010-12-17 NZ NZ600627A patent/NZ600627A/en unknown
- 2010-12-17 MX MX2012007282A patent/MX338323B/es active IP Right Grant
- 2010-12-17 KR KR1020127019503A patent/KR101657737B1/ko active IP Right Grant
- 2010-12-17 HU HUE10810911A patent/HUE028193T2/en unknown
- 2010-12-17 AU AU2010335595A patent/AU2010335595B2/en active Active
- 2010-12-21 AR ARP100104857A patent/AR079683A1/es not_active Application Discontinuation
- 2010-12-22 TW TW099145240A patent/TWI548416B/zh active
- 2010-12-22 UY UY0001033153A patent/UY33153A/es unknown
-
2012
- 2012-06-19 ZA ZA2012/04522A patent/ZA201204522B/en unknown
- 2012-06-21 IL IL220584A patent/IL220584A/en active IP Right Grant
- 2012-06-22 CL CL2012001737A patent/CL2012001737A1/es unknown
- 2012-07-10 CO CO12115592A patent/CO6592047A2/es unknown
-
2013
- 2013-04-26 HK HK13105067.2A patent/HK1178049A1/zh unknown
-
2016
- 2016-07-22 CY CY20161100721T patent/CY1117854T1/el unknown
- 2016-07-27 HR HRP20160954TT patent/HRP20160954T1/hr unknown
- 2016-08-16 SM SM201600277T patent/SMT201600277B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117854T1 (el) | Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1120885T1 (el) | Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
CY1120429T1 (el) | Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
CY1123485T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια νοσων | |
CY1120879T1 (el) | Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος | |
CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
IN2015DN04147A (el) | ||
CY1117582T1 (el) | Χρηση μιμοτοπων των α-συνουκλεϊνης επιτοπων για θεραπεια ασθενειων σωματος lewy | |
BR112012011332A2 (pt) | agentes direcionados para gadd45beta | |
BR112016006564A2 (pt) | proteínas de ligação desmogleína 2 (dsg2) e usos das mesmas | |
CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
MX2009012645A (es) | Formulaciones y metodos para tratar el ojo seco. | |
CY1120642T1 (el) | Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση | |
AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
CY1118967T1 (el) | Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης | |
GT200600277A (es) | Derivados de prostaglandina | |
EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
BR112018012749A2 (pt) | composições para higiene pessoal | |
BR112014000795A2 (pt) | uso cosmético e/ou dermatológico de compostos oligossacarídeos na prevenção e no tratamento de estrias | |
UY33663A (es) | Derivados amínicos para el tratamiento de trastornos proliferativos de la piel | |
CY1124077T1 (el) | Xitozanh aniontikoy φορτιου |